Treatment of childhood acute myeloid leukemia.

Abstract:

:Childhood acute myeloid leukemia is rare, but accounts for a significant number of malignancy-related deaths in this age group. However, the prognosis has improved over past decades, and survival rates of 60% and above have been reported. Still, this implies that more than a third of children and adolescents die from this disease. Moreover, treatment is intensive, and quality of life and late effects are worrying issues. Therefore, there is a need for further improved treatment of pediatric acute myeloid leukemia. This review describes several important developments in this respect, such as improved diagnostics, prognostic factors, subgroup-directed and tailored treatment, and targeted therapy. In addition, background information is provided and current treatment strategies are described, as well as the late effects of treatment. Most groups now have risk-group adapted protocols, with allogeneic stem cell transplantation often being reserved for the higher risk group. Even in these cases, the benefit of stem cell transplantation has not been demonstrated beyond reasonable doubt with current high-intensive chemotherapy. Similarly, the use of cranial irradiation for CNS prophylaxis and maintenance treatment does not seem to be indicated in general. Subgroup-directed treatment has become a reality for acute myeloid leukemia in young children with Down's syndrome and in acute promyelocytic leukemia. In addition to tailoring therapy according to biologic features and especially monitoring treatment by measurements of minimal residual disease, targeted therapy for subgroups with activating mutations in receptor tyrosine kinases will further optimize the treatment of pediatric acute myeloid leukemia. Together with the development of many novel agents that have different mechanisms of action than the currently available anticancer agents, and improved supportive care, it is realistic that the prognosis of acute myeloid leukemia in children and adolescents will improve further in the next 5-10 years.

authors

ter Bals E,Kaspers GJ

doi

10.1586/14737140.5.5.917

keywords:

subject

Has Abstract

pub_date

2005-10-01 00:00:00

pages

917-29

issue

5

eissn

1473-7140

issn

1744-8328

journal_volume

5

pub_type

杂志文章,评审
  • Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.

    abstract:INTRODUCTION:Adrenocortical carcinoma (ACC) is a rare tumor characterized by poor prognosis in most cases. Moreover, in most cases ACC produces an excess of adrenal steroid hormones with relevant clinical consequences. Areas covered: After an extensive literature search, this narrative review addresses diagnostic manag...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1510325

    authors: Puglisi S,Perotti P,Cosentini D,Roca E,Basile V,Berruti A,Terzolo M

    更新日期:2018-11-01 00:00:00

  • Molecular changes in pancreatic cancer.

    abstract::As with many human malignancies, pancreatic cancer is a complex genetic disorder. Several thousand disease-associated alterations on the DNA, mRNA, miRNA and protein levels have been reported to date. Some of these alterations, including a number of gatekeeper mutations, which are of pre-eminent importance for the ons...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.107

    authors: Buchholz M,Gress TM

    更新日期:2009-10-01 00:00:00

  • Clinical implications of lung neuroendocrine neoplasm classification.

    abstract:INTRODUCTION:Neuroendocrine neoplasms of the lung (Lung NENs) encompass NE tumors (NETs), which are in turn split into typical and atypical carcinoids, and NE carcinomas (NECs), which group together small-cell carcinoma and large-cell NE carcinoma. This classification is the current basis for orienting the daily practi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1862654

    authors: Metovic J,Barella M,Harari S,Pattini L,Albini A,Sonzogni A,Veronesi G,Papotti M,Pelosi G

    更新日期:2020-12-24 00:00:00

  • Development of antiangiogenic agents for ovarian cancer.

    abstract::Epithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality, despite advances in surgical and chemotherapeutic management. The molecular pathways that control angiogenesis have been demonstrated to be key to the pathogenesis of EOC, and have been shown to have prognostic significance. Incr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.1.21

    authors: Collinson FJ,Hall GD,Perren TJ,Jayson GC

    更新日期:2008-01-01 00:00:00

  • Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.

    abstract::The monoclonal antibody against HER2, trastuzumab (Herceptin), has become an important player in the treatment of patients with HER2-positive breast cancer. Both in the metastatic and adjuvant setting, the addition of trastuzumab to other systemic treatments has led to a striking increase in tumor response and surviva...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.12.1763

    authors: Perik PJ,de Korte MA,van Veldhuisen DJ,Gietema JA,Sleijfer DT,de Vries EG

    更新日期:2007-12-01 00:00:00

  • Adrenocortical carcinoma: role of laparoscopic surgery in treatment.

    abstract::Adrenocortical carcinoma is a rare disorder with a prevalence of one case per 1.7 million people and a generally poor prognosis. It accounts for 0.02% of all cancer cases and 0.2% of cancer deaths. Within the past three decades, accurate diagnosis, precise radiologic localization, satisfactory preoperative medical man...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.9.1295

    authors: Haleblian GE,Wilson C,Haddad D,Albala DM

    更新日期:2007-09-01 00:00:00

  • Systemic therapy for recurrent endometrial cancer: a review of North American trials.

    abstract::While early-stage endometrial cancer is highly curable after hysterectomy for the majority of patients afflicted with this disease, recurrent and metastatic endometrial cancer continues to pose a significant challenge. The median survival of women with advanced or recurrent uterine cancer on most recent clinical trial...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.54

    authors: Dellinger TH,Monk BJ

    更新日期:2009-07-01 00:00:00

  • Oncolytic viruses: a novel form of immunotherapy.

    abstract::Oncolytic viruses are novel anticancer agents, currently under investigation in Phase I-III clinical trials. Until recently, most studies have focused on the direct antitumor properties of these viruses, although there is now an increasing body of evidence that the host immune response may be critical to the efficacy ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.10.1581

    authors: Prestwich RJ,Harrington KJ,Pandha HS,Vile RG,Melcher AA,Errington F

    更新日期:2008-10-01 00:00:00

  • Immunotherapy options in metastatic renal cell cancer: where we are and where we are going.

    abstract::The treatment of renal cell carcinoma is rapidly changing as a result of recent evidence concerning the efficacy of biological drugs, antiangiogenetic agents and signal-transduction inhibitors. This paper will provide a critical overview of the use of immunotherapy in renal cell carcinoma and review the available data...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.10.1459

    authors: Passalacqua R,Buti S,Tomasello G,Longarini R,Brighenti M,Dalla Chiesa M

    更新日期:2006-10-01 00:00:00

  • The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.

    abstract::The treatment of acute myeloid leukaemia has remained largely unchanged for the last 30 years since the advent of combination chemotherapy with cytarabine arabinoside and daunorubicin with remission rates around 70% but with long term survival still only around 40% in young adults. Doses of chemotherapy have been push...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2016.1162099

    authors: Kell J

    更新日期:2016-01-01 00:00:00

  • Organ preservation strategies in bladder cancer.

    abstract::Bladder cancer is a significant cause of morbidity and mortality. Promising results with organ preservation strategies using multimodality treatment over the last decade offers an option for bladder preservation in a significant proportion of patients who currently undergo cystectomy. The primary goal of the bladder-s...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.6.641

    authors: Hussain SA,James ND

    更新日期:2002-12-01 00:00:00

  • Antineoplastic therapy-induced pulmonary toxicity.

    abstract::Pulmonary complications of antineoplastic therapy are common and are an important cause of respiratory morbidity. The pulmonary toxicity should be taken into account in every patient with respiratory problems who is or has been treated with antineoplastic agents. The diagnosis of drug-induced pulmonary toxicity is com...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.817684

    authors: Sadowska AM,Specenier P,Germonpre P,Peeters M

    更新日期:2013-08-01 00:00:00

  • Advances in the management of testicular cancer.

    abstract::Although testicular cancer is currently a rare disease, the incidence is rising. The most important risk factor remains cryptorchism and there is a variable association with testicular microlithiasis. Serum tumor markers remain important for diagnosis, and they have prognostic value and can be used to monitor therapy ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.4.669

    authors: Balk C,Witjes JA

    更新日期:2004-08-01 00:00:00

  • Optimal treatment of metastatic colorectal cancer.

    abstract::For over 40 years, fluorouracil has been the only drug registered for the treatment of metastatic colorectal cancer. During the past 5 years, combination chemotherapy regimens including either irinotecan or oxaliplatin have proven to be superior to fluorouracil monotherapy in randomized clinical trials, in terms of re...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.5.801

    authors: Pessino A,Sobrero A

    更新日期:2006-05-01 00:00:00

  • Biological agents in head and neck cancer.

    abstract::Survival of head and neck cancer (HNC) patients has not dramatically improved over the last 30 years, despite the advances in surgical techniques, chemotherapeutic agents and radiotherapy treatment planning and definition. Different studies in molecular biology of HNC have been carried out, providing useful results fo...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.11.1643

    authors: Bossi P,Locati LD,Licitra L

    更新日期:2007-11-01 00:00:00

  • Capecitabine in the treatment of colorectal cancer.

    abstract::Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the data in relation to the pharmacology and mode of action of capecitabine, followed by an in-depth review of the available c...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.6.803

    authors: Kelly C,Cassidy J

    更新日期:2007-06-01 00:00:00

  • Clinical outcome after cystectomy in patients with lymph node-positive bladder cancer.

    abstract::Whereas radical cystectomy is the standard of care in high-grade, invasive bladder tumors, the extent of lymphadenectomy and its diagnostic and/or therapeutic potential is controversial. Independent predictors for lymph node involvement are T-stage, histological grading and lymphovascular invasion. Preoperative assess...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.6.871

    authors: Nagele U,Anastasiadis AG,Merseburger AS,Sievert KD,Stenzl A,Kuczyk M

    更新日期:2006-06-01 00:00:00

  • Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.

    abstract::Advanced gastric cancer (GC) is a dreadful disease with a poor prognosis and the majority of patients die within 1 year of diagnosis. In the past decade, important signaling pathways promoting tumor proliferation and aggressiveness have been evaluated; the hepatocyte growth factor/mesenchymal epithelial transition (ME...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.974564

    authors: Abdel-Rahman O

    更新日期:2015-02-01 00:00:00

  • Colorectal cancer screening and diagnosis: omics-based technologies for development of a non-invasive blood-based method.

    abstract::Introduction: Colorectal cancer (CRC) is one of the most important health problems in the Western world. In order to reduce the burden of the disease, two strategies are proposed: screening and prompt detection in symptomatic patients. Although diagnosis and prevention is mainly based on colonoscopy, faecal haemoglobi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1882858

    authors: Gallardo-Gómez M,De Chiara L,Álvarez-Chaver P,Cubiella J

    更新日期:2021-01-28 00:00:00

  • Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.

    abstract:INTRODUCTION:The success of the immune checkpoint inhibitors in melanoma has reinvigorated the field of immunotherapy. Immune checkpoint inhibitors are now the standard of care in multiple cancer types including lung cancer, head and neck cancer, urothelial cancer and renal cell cancer. The field of immunotherapy is cu...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2017.1341315

    authors: O'reilly A,Larkin J

    更新日期:2017-07-01 00:00:00

  • Advances in radiation therapy of head and neck cancer.

    abstract::Head and neck cancer is the fifth most common cancer in the USA. Although there have been major improvements in surgical and radiation techniques, the overall survival has not changed significantly in the last decade. The major changes occurring in recent years have been in the ability to preserve organs and to improv...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.4.633

    authors: Popovtzer A,Eisbruch A

    更新日期:2008-04-01 00:00:00

  • Antiangiogenic therapies: is VEGF-A inhibition alone enough?

    abstract::Although available targeted therapies provide some clinical efficacy, a need remains for antiangiogenic therapies with alternative mechanisms in order to provide better outcomes and the ability to circumvent resistance. Inhibition of multiple VEGF targets may produce enhanced efficacy and more durable responses throug...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/era.11.5

    authors: Gordon MS

    更新日期:2011-03-01 00:00:00

  • Role of MRI for staging of rectal cancer.

    abstract::Total mesorectal excision has been established as a standard surgical procedure for rectal cancer. MRI is now routinely used for preoperative staging of rectal cancer and provides accurate assessment of the tumor relative to the circumferential margin, that is, the mesorectal fascia. This identifies patients at risk o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.09.13

    authors: Jhaveri KS,Sadaf A

    更新日期:2009-04-01 00:00:00

  • Benefits of laparoscopic prostate-sparing radical cystectomy.

    abstract:PURPOSE:Prostate-sparing radical cystectomy has been described in the literature and has proven to be a promising procedure owing to the continence and erectile function results without necessarily compromising the oncologic outcome in selected patients. TECHNIQUE POINTS:A transperitoneal approach is used. Lymph node ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.1.21

    authors: Rozet F,Harmon J,Arroyo C,Cathelineau X,Barret E,Vallancien G

    更新日期:2006-01-01 00:00:00

  • Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.

    abstract::The failure of conventional chemotherapy to improve survival in a large percentage of patients with advanced solid tumors has prompted the development of alternative anticancer approaches. Conventional allogeneic hematopoietic stem cell transplantation (HSCT) relies on myeloablative conditioning to eradicate the under...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.5.865

    authors: Espinoza-Delgado I,Childs RW

    更新日期:2004-10-01 00:00:00

  • Cancer of the nasal cavity and paranasal sinuses.

    abstract::Sinonasal malignancies continue to have poor survival rates. Disease-related mortality is usually the result of disease recurrence and progression at the primary site despite aggressive therapy. Complete surgical excision with postoperative radiation therapy remains the standard of care for resectable lesions. Improve...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.3.411

    authors: Maghami E,Kraus DH

    更新日期:2004-06-01 00:00:00

  • Prodrugs for targeted cancer therapy.

    abstract::Introduction: Prodrugs have been used to improve the selectivity and efficacy of cancer therapy by targeting unique abnormal markers that are overexpressed by cancer cells and are absent in normal tissues. In this context, different strategies have been exploited and new ones are being developed each year. Areas cover...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1615890

    authors: Souza C,Pellosi DS,Tedesco AC

    更新日期:2019-06-01 00:00:00

  • Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.

    abstract::Bacillus Calmette-Guérin (BCG) has been used in the intravesical treatment of urothelial bladder cancer (UBC) for three decades. Despite its efficacy, intravesical BCG therapy is associated with some limitations such as side effects and BCG failure, which have inspired multiple ways to improve it. Recent advances have...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.961430

    authors: Wang Y,Yang M,Yu Q,Yu L,Shao S,Wang X

    更新日期:2015-01-01 00:00:00

  • Small cell carcinoma of the urinary bladder: a contemporary review with a special focus on bladder-sparing treatments.

    abstract::Small cell carcinoma of the urinary bladder (SCCUB) is a rare and aggressive disease. To date, no standard treatment has been proposed due to the lack of prospective studies resulting from the rarity of this disease. Recently published studies of relatively large patient cohorts, however, have shed some light on the m...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.851605

    authors: Koga F,Yokoyama M,Fukushima H

    更新日期:2013-11-01 00:00:00

  • Breast cancer metastasis progression as revealed by intravital videomicroscopy.

    abstract::Metastasis is the spread of cells from a primary tumor to a distant site, where they arrest and grow to form a secondary tumor. Conventional metastasis models have focused primarily on analysis of end point tumor formation following inoculation with tumor cells. This approach can be used to measure the metastatic pote...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.9.1271

    authors: MacDonald IC,Chambers AF

    更新日期:2006-09-01 00:00:00